Curated By Nelson Vergel | ExcelMale.com | Updated March 2026
Key Takeaways
Retatrutide is a first-in-class triple hormone receptor agonist (GLP-1 + GIP + glucagon) from Eli Lilly, currently in Phase 3 clinical trials under the TRIUMPH program.
In Phase 3 (TRIUMPH-4), participants on the...
Retatrutide is the triple-agonist GLP-1/GIP/glucagon peptide outperforming Ozempic and Mounjaro in trials. Complete dosing, results, and safety guide for men.
Could a single weekly injection deliver unprecedented weight loss while preserving muscle mass and improving cardiovascular health? For...